Chordia Therapeutics (TSE:190A) Asset Impairment Charge : 円0.00 Mil (TTM As of Feb. 2025)

View and export this data going back to 2024. Start your Free Trial

What is Chordia Therapeutics Asset Impairment Charge?

Chordia Therapeutics's Asset Impairment Charge for the three months ended in Feb. 2025 was 円0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Feb. 2025 was 円0.00 Mil.

Chordia Therapeutics Asset Impairment Charge Historical Data

The historical data trend for Chordia Therapeutics's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chordia Therapeutics Asset Impairment Charge Chart

Chordia Therapeutics Annual Data

Trend

Aug21

Aug22

Aug23

Aug24

Asset Impairment Charge

Chordia Therapeutics Quarterly Data
	Aug21	Aug22	May23	Aug23	May24	Aug24	Feb25
Asset Impairment Charge	Get a 7-Day Free Trial			-	-	-	-	-

Chordia Therapeutics Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Feb. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0.00 Mil.

Chordia Therapeutics Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Chordia Therapeutics's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Chordia Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chordia Therapeutics Inc (TSE:190A) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

N/A

Address

2-26-1 Muraoka-Higashi, Kanagawa, Fujisawa, JPN, 251-0012

Website

https://www.chordiatherapeutics.com

Chordia Therapeutics Inc is a bio-venture company specializing in cancer research and development. Its mission is to deliver first-in-class cancer drugs to patients. It is a clinical-stage biotech company engaged in researching and developing novel therapies for cancers with high unmet medical needs.

Chordia Therapeutics Headlines

No Headlines